Form 7 Monthly Progress Report November 1 2022
Form 7 Monthly Progress Report November 1, 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 December 6, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended […]
Form 7 Monthly Progress Report October 1 2022
Form 7 Monthly Progress Report November 1, 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 November 1, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended […]
Form 7 Monthly Progress Report – September 2022
Form 7 Monthly Progress Report – August 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 October 2, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended […]
Form 7 Monthly Progress Report – August 2022
Form 7 Monthly Progress Report – August 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 September 1, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended […]
Form 7 Monthly Progress Report – June 2022
Form 7 – Monthly CSE Progress Report June 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 July 4th, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not […]
Form 7 – Monthly CSE Progress Report May 2022
Form 7 – Monthly CSE Progress Report June 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,036,228 June 2nd, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not […]
Liquid Biopsy – What Is It?
A liquid biopsy is a test that is performed on a sample of blood taken from a patient. The test analyzes the blood sample and looks for traces of cancer DNA from tumor cells that are often present in the blood. Multiple blood samples over a period of time allow physicians and doctors to examine […]
10 Reasons why Biomark BUX is a Buy and Long-term Hold
The article presented on this page may contain forward-looking statements. These statements relate to future events or future financial performance. Any statements that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, and similar statements) should be considered forward looking statements. […]
BioMark Diagnostics and Phytronix Technologies Strategic Technology Integration Partnership
The Right Leadership and Technology Partnerships designed to deliver clinical solutions to cancer care management. Dr. Haince bring solid capabilities in clinical development and commercialization of cancer diagnostic tests in N. America, Accreditation and core lab management expertise, scientific rigour and business development capabilities to BioMark as GM and CSO (Chief Scientist Officer). At Diagnocure, […]
Alberta Research to Spot Early Stage Lung Cancer
Earlier and faster cancer detection is underway in Alberta Mikenomics | April 6, 2021 Earlier and faster cancer detection is the goal of research underway here in Alberta.With funding from the Spark Grants, The Metabolomics Innovation Centre (TMIC) based at the University of Alberta is leading the new effort. With funding from the Spark Grants, The Metabolomics Innovation Centre (TMIC) based […]
